Last patient completes the TRIAC-1 trial

RTT announced today that the last patient has completed the last visit in the TRIAC1 trial, evaluating the effects of Emcitate on the peripheral symptoms of MCT8 deficiency. The study, which was initiated and conducted by Erasmus Medical Center in Rotterdam, was started in 2016 and has followed 46  patients with MCT8 deficiency from nine different  countries treated with Emcitate for one year. Final study results are expected to be presented in the beginning of 2019.

Leave a Reply

Your email address will not be published. Required fields are marked *